Tracy Norfleet, MD
Internal Medicine · Saint Louis, MONPI 1487680377
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,525 of the $132,044 with a category attached, or 64.8%. Lilly USA, LLC accounts for 85.7% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $86,543, more than ten times the $494 reported in 2019. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $354.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$113K
- Currax Pharmaceuticals LLC$11K
- Edwards Lifesciences$5K
- Novo Nordisk$819
- AbbVie$413
- Astellas Pharma US Inc$229
- plus $2K from 22 others
What the payments were for
- Consulting fees$14,51311%
- Speaking & faculty fees$85,52565%
- Travel & lodging$24,42818%
- Food & beverage$7,5026%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 211 | $113,122 |
| Currax Pharmaceuticals LLC | 11 | $10,803 |
| Edwards Lifesciences | 12 | $5,103 |
| Novo Nordisk | 24 | $819 |
| AbbVie | 26 | $413 |
| Astellas Pharma US Inc | 10 | $229 |
| Vivus LLC | 2 | $217 |
| GSK | 9 | $144 |
| Johnson & Johnson(2 entities) | 8 | $138 |
| Exact Sciences | 7 | $137 |
| Amgen | 7 | $124 |
| AstraZeneca | 8 | $124 |
| UCB, Inc. | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $91 |
| Abbott | 4 | $86 |
| Pfizer | 4 | $67 |
| Boehringer Ingelheim | 3 | $55 |
| Viiv Healthcare Company | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Recor Medical Inc | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,044 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $73,970 |
| EliquisApixaban | 75 | $66,944 |
| XareltoRivaroxaban | 50 | $45,486 |
| JardianceEmpagliflozin | 39 | $38,154 |
| MounjaroTirzepatide | 29 | $33,370 |
| MyrbetriqMirabegron | 50 | $28,664 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,912 |
| FarxigaDapagliflozin Propanediol | 29 | $20,571 |
| TrulicityDulaglutide | 12 | $14,656 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 57 | $14,357 |
| JanuviaSitagliptin Phosphate | 13 | $11,723 |
| LinzessLinaclotide | 13 | $10,283 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,696 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,894 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $819 | $73,97066 claims |
| PfizerEliquis | $67 | $66,94475 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $55 | $50,67463 claims |
| Lilly USA, LLCMounjaro, Trulicity | $113,122 | $48,02641 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Arnuity Ellipta | $144 | $47,375101 claims |
| Johnson & JohnsonXarelto | $138 | $45,48650 claims |
| Astellas Pharma US IncMyrbetriq | $229 | $28,66450 claims |
| AstraZenecaFarxiga, Symbicort | $124 | $28,26749 claims |
| AbbVieLinzess, Synthroid | $413 | $14,30057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
- Uladzislau NaidzionakSaint Louis$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.